MGM Resorts International vs Viatris Inc — how do they compare? MGM Resorts International trades at $29.27 (market cap $7.55B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.7× MGM Resorts International's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Viatris Inc for 57 Days on average.
| MGM | VTRS | |
|---|---|---|
Market Cap | $7.55B | $20.03B |
Volume | 5,342,346 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $18.27 |
52-Week Low | $29.27 | $9.74 |
Typical Hold Time | 91 Days | 57 Days |
Enterprise Value | $34.85B | $32.15B |
Dividend Yield | 0.03% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement. The stock is in a bearish technical trend with recent pressure following the collapse of a proposed acquisition by Barry Diller's People Inc. Fundamentally, revenue remains stable near $17.5 billion, but net income margin has compressed to 2.4% in 2025. The company maintains strong operating cash flow of $2.53 billion, though net cash flow was negative $338 million. Analyst sentiment is mixed but leans positive, with a consensus price target of $48.75 implying significant upside.
The investment outlook for MGM hinges on its ability to stabilize profitability and navigate deal uncertainty. The primary opportunity lies in the substantial discount to analyst targets, while risks include execution on potential acquisitions, competitive pressures in the gaming sector, and macroeconomic sensitivity. The stock's current valuation multiples, such as a P/E of 18.19, appear reasonable if earnings can recover.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →